Laurent Pharmaceuticals Inc.
$7,000,000.00 CAD
- Department
- National Research Council Canada
- Recipient country
- Canada
- Fiscal year
- 2022-2023
- Agreement period
- February 1, 2023 – March 31, 2025
- Reference
- nrc-cnrc:172-2022-2023-Q4-1002706
Published purpose
The project is focusing on Phase 3 pivotal study of LAU-7b in moderate-to-severe hospitalized COVID-19 patients, and has a component allowing the transition to a new Phase 2 clinical development in mild-to-moderate non-hospitalized COVID-19 patients. LAU-7b is a next-generation COVID-19 antiviral that addresses the gap between early infection and critical COVID-19 disease, and aims for broad applicability at-home or in hospital. Because its host-directed mechanism, LAU-7b has the potential to work on all mutations of COVID-19, and other coronaviruses. Results from the Phase 2 pilot study showed 100% reduction in the risk of progression to mechanical ventilation and death in hospitalized moderate-to-severe patient.
In plain English AI-generated
Funding supports a Phase 3 clinical trial of LAU-7b, an antiviral drug for treating hospitalized COVID-19 patients, with potential expansion to non-hospitalized cases.
Category: Health Primarily funds activity in Canada
Based on the published description. See how AI categorization works — the linked official record is authoritative.
Community tags
Tags are applied by readers, not by this site. One tag per person per record.